# A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

Study · id `cardio:ct-nct06522997` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06522997](<https://clinicaltrials.gov/study/NCT06522997>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06522997

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1222 participants.

## Technical summary

Registry record NCT06522997. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-08 (actual); primary completion 2025-10-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 1222 participants (enrolled count; ClinicalTrials.gov record NCT06522997, source copy `cardio:ctgov-nct06522997-2026-04-13`, retrieved 2026-10-26)
- Started: 2024-08-08 (actual) (ClinicalTrials.gov record NCT06522997, source copy `cardio:ctgov-nct06522997-2026-04-13`, retrieved 2026-10-26)
- Primary completion: 2025-10-24 (actual) (ClinicalTrials.gov record NCT06522997, source copy `cardio:ctgov-nct06522997-2026-04-13`, retrieved 2026-10-26)
- Completion: 2025-11-20 (actual) (ClinicalTrials.gov record NCT06522997, source copy `cardio:ctgov-nct06522997-2026-04-13`, retrieved 2026-10-26)
- Countries: United States; Argentina; Belgium; China; Greece; India; Italy; Japan; Portugal; Singapore; Slovakia; Spain; Sweden; Taiwan; United Kingdom (ClinicalTrials.gov record NCT06522997, source copy `cardio:ctgov-nct06522997-2026-04-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06522997-2026-04-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
- Acronym: ALPINE 1
- Condition: Chronic Kidney Disease
- Intervention (Drug): BAY3283142
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 7d24d0304e2343decd5609ec8cc965bb6161c405b6d274f026a1897c58968d81
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
